Physician

Daniel Andrew Chruscicki, M.D.

According to 2025 Medicare claims, Daniel Chruscicki, M.D. (NPI: 1861666463) practices ophthalmology in the Lincoln, NE market, with the plurality of this provider's patient population coming from Lancaster, NE. This provider's primary affiliated billing organization is EYE SURGICAL ASSOCIATES, LLC (NPI: 1417952995; TIN: 47-0626698) and primary practice location at 68506-1676.

Chruscicki's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,750 traditional Medicare patients, billed 52,021 HCPCS/CPT codes, and received $3,196,692 in Medicare payments. The top billing code was 92235 (Exam of retinal blood vessels using a special camera after injection of a dye). Part D data shows 887 prescription claims across 225 beneficiaries totaling $33,077 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 6 records totaling $85. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $24,156 to $33,077. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.9M$3.8M2015 Medicare payment: $2,759,456 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $2,751,997 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $2,920,805 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $3,071,143 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $3,227,210 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $3,602,106 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $3,715,292 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $3,771,175 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $3,093,757 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $3,196,692 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,62412,399$2,759,456
20161,61013,845$2,751,997
20171,58714,680$2,920,805
20181,43815,033$3,071,143
20191,46015,638$3,227,210
20201,86118,386$3,602,106
20211,76918,726$3,715,292
20221,79721,271$3,771,175
20231,71948,700$3,093,757
20241,75052,021$3,196,692

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$20K$40K2015 Drug cost: $24,156 (USD; Tot_Drug_Cst)2016 Drug cost: $19,923 (USD; Tot_Drug_Cst)2017 Drug cost: $23,383 (USD; Tot_Drug_Cst)2018 Drug cost: $18,798 (USD; Tot_Drug_Cst)2019 Drug cost: $21,520 (USD; Tot_Drug_Cst)2020 Drug cost: $24,831 (USD; Tot_Drug_Cst)2021 Drug cost: $38,621 (USD; Tot_Drug_Cst)2022 Drug cost: $39,728 (USD; Tot_Drug_Cst)2023 Drug cost: $34,745 (USD; Tot_Drug_Cst)2024 Drug cost: $33,077 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201587367$24,156
201699352$19,923
201792361$23,383
201883324$18,798
2019103362$21,520
2020120486$24,831
2021149615$38,621
2022160615$39,728
2023164660$34,745
2024225887$33,077

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
92235Exam of retinal blood vessels using a special camera after injection of a dye576719$113
92014Established patient complete exam of visual system1,4562,493$81
67028Injection of drug into eye5102,363$77
92134Imaging of retina1,3743,396$26
92250Photography of the retina619764$23

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate28710,897$13,899
Ketorolac TromethamineKetorolac Tromethamine2326,835$5,503
LumiganBimatoprost13787$4,339
Atropine SulfateAtropine Sulfate1073,947$3,616
OfloxacinOfloxacin1102,803$1,678

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.6$85Apellis Pharmaceuticals, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Daniel Andrew Chruscicki, M.D.?

Tedicare shows public-source Medicare data for Daniel Andrew Chruscicki, M.D. (NPI 1861666463), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Andrew Chruscicki, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Daniel Andrew Chruscicki, M.D.?

Daniel Andrew Chruscicki, M.D. is linked to EYE SURGICAL ASSOCIATES, LLC (billing NPI 1417952995) in the available physician profile data.

Does Daniel Andrew Chruscicki, M.D. have Open Payments data?

Daniel Andrew Chruscicki, M.D. has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.